Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Human/Mouse/Rat iNOS Antibody, R&D Systems™

Mouse Monoclonal Antibody has been used in 15 publications
Supplier: R&D Systems MAB9502
This item is not returnable.
View return policy
Description
iNOS Monoclonal specifically detects iNOS in Human, Mouse, Rat samples. It is validated for Western Blot, Simple Western, Immunohistochemistry.Specifications
iNOS | |
Monoclonal | |
Unconjugated | |
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS. with No Preservative | |
EC 1.14.13.39, Hepatocyte NOS, HEP-NOS, Inducible NO synthase, Inducible NOS, INOS, nitric oxide synthase 2, inducible, nitric oxide synthase 2A (inducible, hepatocytes), nitric oxide synthase, inducible, nitric oxide synthase, macrophage, NOS, NOS type II, NOS2, NOS2A, Peptidyl-cysteine S-nitrosylase NOS2 | |
Mouse | |
Protein A or G purified from ascites | |
RUO | |
4843 | |
Reconstitute at 0.5 mg/mL in sterile PBS. | |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution. | |
IgG1 |
Western Blot, Immunohistochemistry | |
2D2-B2 | |
Western Blot 1 ug/mL, Simple Western 10 ug/mL, Immunohistochemistry 8-25 ug/mL | |
P35228 | |
NOS2 | |
Recombinant human iNOS Pro781-His798 Accession # P35228 | |
100 μg | |
Primary | |
Detects human iNOS. By using synthetic peptides, the epitope recognized by this antibody has been mapped to aa 781-798 of human iNOS. The corresponding sequence of mouse iNOS is identical. | |
Human, Mouse, Rat | |
Purified |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction